{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:55:07Z","timestamp":1791420907696,"version":"4.3.3"},"reference-count":50,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1\u2013dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4\/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and 3-deoxy-3[18F]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUVmax), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of &gt; 1 year (range, 14.9-30.1+ months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated &gt; 70%, &gt; 90%, and \u2265 87.5% reductions in summed FLT SUVmax and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4\/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056.<\/jats:p>","DOI":"10.1182\/blood-2011-10-388298","type":"journal-article","created":{"date-parts":[[2012,3,3]],"date-time":"2012-03-03T22:59:06Z","timestamp":1330815546000},"page":"4597-4607","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":275,"title":["Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"119","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Lymphoma Service, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R.","family":"Chirieac","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Q.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Nuclear Medicine Service, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Vallabhajosula","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiochemistry and Radiopharmacy, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schoder","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"English","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Millenson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Lymphoma Service, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Ely","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Courtney","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Shaik","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Wilner","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Randolph","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick D.","family":"Van den Abbeele","sequence":"additional","affiliation":[{"name":"Department of Imaging, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina Y.","family":"Chen-Kiang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Imaging, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Early Drug Development Center, Dana-Farber Cancer Institute, Boston, MA; and"},{"name":"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807502138900_B1","article-title":"International Agency for Research on Cancer.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"issue":"4","key":"2019111807502138900_B2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807502138900_B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11899-009-0028-z","article-title":"Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.","volume":"4","author":"Kahl","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2019111807502138900_B4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/fon.10.189","article-title":"Should there be a standard therapy for mantle cell lymphoma?","volume":"7","author":"Smith","year":"2011","journal-title":"Future Oncol"},{"issue":"1","key":"2019111807502138900_B5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options.","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2019111807502138900_B6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3816\/CLM.2009.n.055","article-title":"Mantle cell lymphoma: biological insights and treatment advances.","volume":"9","author":"Leonard","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"2019111807502138900_B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"4656","key":"2019111807502138900_B8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation.","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"issue":"21","key":"2019111807502138900_B9","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","article-title":"PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111807502138900_B10","first-page":"5541s","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma.","volume":"52","author":"Williams","year":"1992","journal-title":"Cancer Res"},{"issue":"8","key":"2019111807502138900_B11","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma.","volume":"84","author":"Bosch","year":"1994","journal-title":"Blood"},{"issue":"9","key":"2019111807502138900_B12","first-page":"1833","article-title":"Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma.","volume":"10","author":"de Boer","year":"1995","journal-title":"Oncogene"},{"issue":"10","key":"2019111807502138900_B13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2019111807502138900_B14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment.","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807502138900_B15","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2019111807502138900_B16","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma.","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"2019111807502138900_B17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111807502138900_B18","first-page":"2409","article-title":"BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas.","volume":"61","author":"Be\u00e0","year":"2001","journal-title":"Cancer Res"},{"issue":"8","key":"2019111807502138900_B19","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2002-01-0263","article-title":"Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.","volume":"101","author":"Quintanilla-Martinez","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111807502138900_B20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol is untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111807502138900_B21","doi-asserted-by":"crossref","first-page":"A8563","DOI":"10.1200\/jco.2009.27.15_suppl.8563","article-title":"Phase I\/II study of a hybrid schedule of flavopiridol in relapsed\/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) [abstract].","volume":"27","author":"Tay","year":"2009","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"7","key":"2019111807502138900_B22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdi217","article-title":"In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.","volume":"16","author":"Lacrima","year":"2005","journal-title":"Ann Oncol"},{"issue":"16","key":"2019111807502138900_B23","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1158\/0008-5472.CAN-09-3578","article-title":"Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"2019111807502138900_B24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111807502138900_B25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6.","volume":"48","author":"Toogood","year":"2005","journal-title":"J Med Chem"},{"issue":"2","key":"2019111807502138900_B26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer.","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111807502138900_B27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1).","volume":"104","author":"Schwartz","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"2019111807502138900_B28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMc0808558","article-title":"Treatment of growing teratoma syndrome.","volume":"360","author":"Vaughn","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111807502138900_B29","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.2967\/jnumed.107.046391","article-title":"Imaging of cell proliferation: status and prospects.","volume":"49","author":"Bading","year":"2008","journal-title":"J Nucl Med"},{"issue":"12","key":"2019111807502138900_B30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MNM.0b013e32832ee93b","article-title":"Molecular PET and PET\/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.","volume":"30","author":"Barwick","year":"2009","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2019111807502138900_B31","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111807502138900_B32","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"14","key":"2019111807502138900_B33","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","article-title":"A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.","volume":"10","author":"Haddad","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111807502138900_B34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.pas.0000126054.95798.94","article-title":"Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody.","volume":"28","author":"Cheuk","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"2019111807502138900_B35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111807502138900_B36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111807502138900_B37","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111807502138900_B38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/gcc.20754","article-title":"Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.","volume":"49","author":"Espinet","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"2019111807502138900_B39","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111807502138900_B40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"issue":"15","key":"2019111807502138900_B41","first-page":"3783","article-title":"Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.","volume":"59","author":"Harada","year":"1999","journal-title":"Cancer Res"},{"issue":"11","key":"2019111807502138900_B42","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.4161\/cc.6.11.4312","article-title":"CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA.","volume":"6","author":"Thoms","year":"2007","journal-title":"Cell Cycle"},{"issue":"12","key":"2019111807502138900_B43","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.2967\/jnumed.111.094698","article-title":"A pilot study to evaluate 3\u2032-deoxy-3\u2032-18F-fluorothymidine PET for initial and early response imaging in mantle cell lymphoma.","volume":"52","author":"Herrmann","year":"2011","journal-title":"J Nucl Med"},{"issue":"14","key":"2019111807502138900_B44","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res"},{"issue":"15","key":"2019111807502138900_B45","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6.","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"2019111807502138900_B46","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"28","key":"2019111807502138900_B47","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure.","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"issue":"6","key":"2019111807502138900_B48","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and Retinoblastoma Determines Response to CDK4\/6 Inhibition in Ovarian Cancer.","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111807502138900_B49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ccr.2010.05.025","article-title":"A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.","volume":"18","author":"Puyol","year":"2010","journal-title":"Cancer Cell"},{"key":"2019111807502138900_B50","first-page":"PP01","article-title":"Phase I\/II pharmacodynamic trial of PD0332991 in patients with KRAS mutant colorectal cancer [abstract].","volume":"22","author":"O'Dwyer","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/20\/4597\/1351796\/zh802012004597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/20\/4597\/1351796\/zh802012004597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T23:37:46Z","timestamp":1713656266000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/20\/4597\/29970\/Selective-CDK46-inhibition-with-tumor-responses-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":50,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,5,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-388298","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}